AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sodium/potassium-transporting ATPase subunit alpha-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P50993

UPID:

AT1A2_HUMAN

Alternative names:

Sodium pump subunit alpha-2

Alternative UPACC:

P50993; D3DVE4; Q07059; Q5JW74; Q86UZ5; Q9UQ25

Background:

The Sodium/potassium-transporting ATPase subunit alpha-2, also known as Sodium pump subunit alpha-2, plays a pivotal role in maintaining the electrochemical gradient of sodium and potassium across the plasma membrane. This process is fundamental for various cellular functions, including nutrient transport.

Therapeutic significance:

Given its crucial role in cellular processes, the Sodium/potassium-transporting ATPase subunit alpha-2 is linked to several diseases, such as Migraine, familial hemiplegic, 2, Alternating hemiplegia of childhood 1, and Developmental and epileptic encephalopathy 98. Targeting this protein could lead to innovative treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.